title: Pure red cell aplasia associated with dapsone therapy.
authors.forename: Joaquín
authors.initials: J
authors.lastname: Borrás-Blasco
authors.forename: Venancio
authors.initials: V
authors.lastname: Conesa-García
authors.forename: Andrés
authors.initials: A
authors.lastname: Navarro-Ruiz
authors.forename: Pedro
authors.initials: P
authors.lastname: Devesa
authors.forename: Jaime
authors.initials: J
authors.lastname: Matarredona
authors.forename: Francisca
authors.initials: F
authors.lastname: Marín-Jiménez
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001803:Blood Transfusion; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016460:Granuloma Annulare / Q000188:drug therapy; D006801:Humans; D008297:Male; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003622:Dapsone